Mechanism-first science for a body that's finally being heard.
MetIQ develops non-drug metabolic systems and publishes the mechanism behind them. No hype, no black boxes — receptor pathways, disclosed formulations, and the literature that supports them.
One system for the whole incretin axis.
GLP-III is a patent-pending, non-drug, non-stimulant formulation designed to support signaling across all three incretin-adjacent receptor families at once — rather than saturating one and calling it a solution.
The mechanism, in one figure
Three receptors, three jobs
Each of the three governs a different job: GLP-1 carries appetite and fullness cues, GIP carries the nutrient-response signal that follows a meal, and glucagon carries daily energy balance. They are separate conversations, not one switch.
Most of this category engages one of the three and lets the market assume the rest. GLP-III is formulated to support all three. Below, each node names a receptor and the function associated with it — so the claim can be checked against the biology.
Everyone learned the word GLP-1. Almost no one learned the mechanism.
In three years an incretin peptide went from a footnote in endocrinology journals to a household term. What did not travel with it was the biology: that GLP-1 is one signal inside a coordinated system, that receptor sensitivity is a cellular property, and that these pathways can be addressed without a prescription pen.
That gap between awareness and understanding is where the market currently sells hope. We would rather publish the mechanism and let people decide.
Scientific Authority
We publish the mechanism before we sell the product. Books and explainers first, formulation second.
Premium & Precise
Disclosed dosing, bioavailable forms, and a full ingredient panel. No proprietary blends hiding behind a trademark.
Built for the Long Term
Metabolic health compounds over decades. Our claims are scoped to what we can defend in ten years.
The Triple Metabolic System
PATENT PENDING · NON-DRUG · NON-STIMULANT
Support for all three incretin-adjacent receptor families in one non-drug, non-stimulant formulation. Patent pending, disclosed dosing, no proprietary blend.
The Cell's Oldest Language
A DEFINITIVE GUIDE TO MITOCHONDRIA & METABOLISM
Two billion years ago a free-living bacterium struck a deal with a larger cell: unlimited energy for a place to live. That conversation has been running ever since — and this book translates it without losing the rigor a clinician would demand.
Get the mechanism, not the marketing.
Launch dates, new articles, and Book Two progress. Roughly monthly, no drip sequences.
We send launch notices and new articles. No drip sequences.
Received — we'll be in touch.